| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23029 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with mCRPC in whom chemotherapy in not clinically indicated |
| Assessment Process | |
| Rapid review commissioned | 31/05/2023 |
| Rapid review completed | 13/06/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with abiraterone and prednisone or prednisolone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/06/2023 |
| Pre-submission consultation with Applicant | 09/08/2023 |
| Full submission received from Applicant | 31/01/2024 |
| Preliminary review sent to Applicant | 21/11/2024 |
| NCPE assessment re-commenced | 19/12/2024 |
| Follow-up to preliminary review sent to Applicant | 13/02/2025 |
| NCPE assessment re-commenced | 11/03/2025 |
| Factual accuracy sent to Applicant | 28/04/2025 |
| NCPE assessment re-commenced | 02/05/2025 |
| NCPE assessment completed | 10/06/2025 |
| NCPE assessment outcome | The NCPE recommends that olaparib (Lynparza®) not be considered for reimbursement, for this indication, unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.